Jci_page_head_homepage_01 Jci_page_head_homepage_02
Sumin Kang, Shannon Elf, Katherine Lythgoe, Taro Hitosugi, Jack Taunton, Wei Zhou, Li Xiong, Dongsheng Wang, Susan Muller, Songqing Fan, Shi-Yong Sun, Adam I. Marcus, Ting-Lei Gu, Roberto D. Polakiewicz, Zhuo (Georgia) Chen, Fadlo R. Khuri, Dong M. Shin, Jing Chen
Published in Volume 120, Issue 4
J Clin Invest. 2010; 120(4):1165–1177 doi:10.1172/JCI40582
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 4
RNAi-mediated stable knockdown of RSK2 significantly attenuates the metastatic potential of M4e cells in a xenograft nude mouse model.

(A) Immunoblotting results confirm the stable knockdown of RSK2 in the M4e-pLKO.1-RSK2 shRNA cells. (B) Representative images of IHC staining of human vimentin in mouse LNM by M4e-pLKO.1 (brown), compared with LNs from nude mice receiving M4e-pLKO.1-RSK2 shRNA cells, to determine LNM. Original magnification, ×40. (C) RNAi-mediated downregulation of RSK2 did not affect tumor formation of metastatic M4e cells in vivo. Tumors from xenograft nude mice injected with control M4e-pLKO.1 cells or M4e-pLKO.1-RSK2 shRNA cells were harvested and weighed at the experimental end point. Individual points represent differential weights of tumors from distinct mice in each group. Average values are represented by horizontal bars. The P value was determined by 2-tailed Student’s t test. (D) Representative images of IHC staining of Ki-67 (brown) from mice injected with either M4e-pLKO.1 or M4e-pLKO.1-RSK2 shRNA cells. Original magnification, ×400.